Mariner’s Karyopharm Therapeutics KPTI Stock Holding History

Mariner’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,332	Closed	-$35.8K	–	2966
2023 Q2	$35.8K	Sell	1,332 -538	-29%	-$23.2K	﹤0.01%	2745
2023 Q1	$109K	Buy	+1,870	New	+$92.3K	﹤0.01%	2564
2022 Q4	–	Sell	-1,114	Closed	-$91K	–	2789
2022 Q3	$91K	Buy	+1,114	New	+$83.2K	﹤0.01%	2222

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mariner's KPTI Position: Q3 2023 in Review

Mariner sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 1,332 shares — an estimated $35.8K sold.

Mariner first reported a position in KPTI in Q3 2022 and held it in 3 quarters. The position peaked at $109K in Q1 2023. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

Mariner reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
Mariner sold 1,332 Karyopharm Therapeutics shares in Q3 2023, an estimated $35.8K.
Mariner first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 3 quarters.
Mariner's Karyopharm Therapeutics position peaked at $109K in Q1 2023.
118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Mariner's 13F filing for Q3 2023, filed 13 Nov 2023.